Expression of matrix metalloproteinases and their association with clinical characteristics of solid tumors

被引:12
|
作者
li, Meng
Yan, Tingting
Cai, Yanqiu
Wei, Yingyuan
Xie, Qiqi [1 ]
机构
[1] Qinghai Univ, Affiliated Hosp, Breast Dis Diag & Treatment Ctr, Xining 810000, Peoples R China
关键词
MMPs; Solid tumor invasion; Metastasis markers; SQUAMOUS-CELL CARCINOMA; LYMPH-NODE METASTASIS; COLORECTAL-CANCER; E-CADHERIN; PROGNOSTIC-SIGNIFICANCE; MESENCHYMAL TRANSITION; TISSUE INHIBITORS; PROSTATE-CANCER; TGF-BETA; MMP-9;
D O I
10.1016/j.gene.2022.146927
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Matrix metalloproteinases (MMPs) are a group of zinc-dependent enzyme families that play an important role in regulating human physiological as well as pathological processes, especially in malignant tumors. Numerous experimental studies have shown that MMPs are not only involved in the occurrence and development of solid tumors but also play a key role in the staging and grading of tumors. The specific processes by which MMPs are involved in tumor cell invasion and metastasis mainly include degradation of the extracellular matrix, regulation of gene polymorphism, promotion of epithelial-mesenchymal transformation, and induction of adhesion mole-cule expression. The correlated expression of MMPs in different solid tumors provides a basis for tumor markers, tumor prognosis, and drug targets. In this review, the function, classification, and nomenclature of MMPs will be summarized, and the relevant expression of MMPs in solid tumors, as well as the clinical survival rate and general prognosis associated with MMPs, will be elaborated to provide useful information on which to base the search for new targets for tumor therapy.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Matrix metalloproteinases and their inhibitors in human pituitary tumors
    Beaulieu, E
    Kachra, Z
    Mousseau, N
    Delbecchi, L
    Hardy, J
    Béliveau, R
    NEUROSURGERY, 1999, 45 (06) : 1432 - 1440
  • [22] Expression of matrix metalloproteinases in gastric carcinoma and possibility of clinical application of matrix metalloproteinase inhibitor in vivo
    Otani, Y
    Kubota, T
    Sakurai, Y
    Igarashi, N
    Yokoyama, T
    Kimata, M
    Wada, N
    Kameyama, K
    Kumai, K
    Okada, Y
    Kitajima, M
    INHIBITION OF MATRIX METALLOPROTEINASES: THERAPEUTIC APPLICATIONS, 1999, 878 : 541 - 543
  • [23] Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human chondrosarcomas
    Söderström, M
    Aro, HT
    Ahonen, M
    Johansson, N
    Aho, A
    Ekfors, T
    Böhling, T
    Kähäri, VM
    Vuorio, E
    APMIS, 2001, 109 (04) : 305 - 315
  • [24] Nevogenesis and differential expression of matrix metalloproteinases
    Gontier, E
    Surleve-Bazeille, J
    Cario-Andre, M
    Taieb, A
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2001, 117 (02) : 512 - 512
  • [25] Expression of matrix metalloproteinases and their inhibitors in retinoblastoma
    Adithi, Mohan
    Nalini, Venkatesan
    Kandalam, Mallikaijuna
    Krishnakumar, Subramanian
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2007, 29 (06) : 399 - 405
  • [26] Expression of matrix metalloproteinases in vasculitic neuropathy
    Gurer, G
    Erdern, S
    Kocaefe, Ç
    Özgüç, M
    Tan, E
    RHEUMATOLOGY INTERNATIONAL, 2004, 24 (05) : 255 - 259
  • [27] Matrix metalloproteinases and their expression in mammary gland
    Uria J.A.
    Werb Z.
    Cell Research, 1998, 8 (3) : 187 - 194
  • [28] Expression of matrix metalloproteinases in ameloblastoma.
    Pinheiro, JJV
    Loureiro, V
    Todai, E
    Jaeger, RG
    JOURNAL OF DENTAL RESEARCH, 2001, 80 (04) : 1005 - 1005
  • [29] Expression of matrix metalloproteinases in vasculitic neuropathy
    Gunfer Gurer
    Sevim Erdem
    Çetin Kocaefe
    Meral Özgüç
    Ersin Tan
    Rheumatology International, 2004, 24 : 255 - 259
  • [30] Expression and Activity of Matrix Metalloproteinases in Leukemia
    Asnafi, Ali Amin
    Bagheri, Marziye
    Zibara, Kazem
    Behzad, Masumeh Maleki
    Shahrabi, Saeid
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2019, 41 (02) : 87 - 95